Valuation: SpectraCure AB

Market Cap 82.74L 8L 7L 7L 6L 11.77L 7.92Cr 11.96L 32.53L 4.14Cr 31.34L 30.69L 13Cr P/E 2024
-10.6x
P/E 2025 -0.79x
Enterprise Value -24.62L -2L -2L -2L -2L -4L -2.36Cr -4L -10L -1.23Cr -9L -9L -3.94Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
28.24%
Yield 2024 *
-
Yield 2025 -
1 day+4.83%
1 week-6.75%
Current month-18.28%
1 month-20.00%
3 months-64.65%
6 months-78.35%
Current year-90.24%
1 week 0.01
Extreme 0.013
0.02
1 month 0.01
Extreme 0.013
0.02
Current year 0.01
Extreme 0.013
0.17
1 year 0.01
Extreme 0.013
0.24
3 years 0.01
Extreme 0.013
5.44
5 years 0.01
Extreme 0.013
10.98
10 years 0.01
Extreme 0.013
45.15
Manager TitleAgeSince
Chief Executive Officer 54 01/10/2025
Director of Finance/CFO - 01/06/2026
Chief Tech/Sci/R&D Officer - 07/10/2025
Director TitleAgeSince
Director/Board Member 63 31/08/2012
Director/Board Member 72 01/01/2022
Chairman 74 01/01/2022
Date Insider Type Main position Quantity % Market Cap. Importance
26/05/23 Buy

Chairman

25,000 0.0257%
30/08/22 Buy

Director

25,000 0.0257%
09/07/22 Sell

Director

10,48,493 1.0795%
Change 5-day change 1-year change 3-year change Capi.($)
+4.83%-6.75%-91.64%-99.55% 8L
-1.35%+2.79%+25.16%+44.93% 26TCr
-1.65%+1.85%+8.11%+8.68% 16TCr
+1.46%+1.27%-5.54%+58.38% 15TCr
+1.23%+2.49%-55.31%-11.12% 6.43TCr
-1.01%+3.53%-15.17%-10.86% 5.19TCr
+1.99%+6.88%+10.60%+56.41% 5.03TCr
+0.89%+1.39%+16.34%+26.80% 4.99TCr
-1.27%-0.37%+19.37%+55.88% 4.88TCr
-0.64%+0.43%+26.45%+71.98% 4.29TCr
Average +0.38%+1.87%-6.16%+20.15% 8.75TCr
Weighted average by Cap. -0.39%+3.42%+6.83%+34.71%

Financials

2024 2025
Net sales - -
Net income -2.3Cr -23.23L -20.7L -19.18L -17.44L -32.72L -22Cr -33.26L -90.46L -12Cr -87.14L -85.32L -37Cr -5.61Cr -56.62L -50.47L -46.75L -42.51L -79.77L -54Cr -81.08L -2.21Cr -28Cr -2.12Cr -2.08Cr -90Cr
Net Debt -1.31Cr -13.26L -11.82L -10.95L -10L -18.68L -13Cr -18.98L -51.63L -6.57Cr -49.74L -48.69L -21Cr -1.07Cr -10.84L -10L -9L -8L -15.27L -10Cr -15.52L -42.22L -5.37Cr -40.67L -39.82L -17Cr
Projected Income Statement - Annual - SpectraCure AB
Logo SpectraCure AB
SpectraCure AB (publ) is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in cancer treatment technology. The Company develops photodynamic therapeutics based on photosensitive materials activated by laser. The Company's method is called interstitial photodynamic therapy (PDT). Interstitial PDT can be used for solid tumors in internal organs, such as cancer in the prostate, pancreas, and the head and neck area, among others. In addition, the Company offers software platform IDOSE for interstitial PDT treatment of solid cancer tumors in internal organs. With SpectraCure’s interstitial PDT method, the patient is given a photoactivated drug - photosensitizer in combination with laser light guided by a dose control system.
Employees
13
Date Price Change Volume
19/26/19 SEK 0.0152 +4.83% 49,12,434
16/26/16 SEK 0.0145 +0.69% 1,41,26,631
15/26/15 SEK 0.0144 -6.49% 2,09,97,956
14/26/14 SEK 0.0154 +2.67% 62,87,169
13/26/13 SEK 0.0150 -7.98% 1,66,63,716
  1. Stock Market
  2. Stocks
  3. SPEC Stock